Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.

Liu, Deli; Shoag, Jonathan E; Poliak, Daniel; Goueli, Ramy S; Ravikumar, Vaishali; Redmond, David; Vosoughi, Aram; Fontugne, Jacqueline; Pan, Heng; Lee, Daniel; Thomas, Domonique; Salari, Keyan; Wang, Zongwei; Romanel, Alessandro; Te, Alexis; Lee, Richard; Chughtai, Bilal; Olumi, Aria F; Mosquera, Juan Miguel; Demichelis, Francesca; Elemento, Olivier; Rubin, Mark A; Sboner, Andrea; Barbieri, Christopher E.
Nat Commun; 11(1): 1987, 2020 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-32332823
Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is among the most common diseases affecting aging men, but the underlying molecular features remain poorly understood, and therapeutic options are limited. Here we employ a comprehensive molecular investigation of BPH, including genomic, transcriptomic and epigenetic profiling. We find no evidence of neoplastic features in BPH no evidence of driver genomic alterations, including low coding mutation rates, mutational signatures consistent with aging tissues, minimal copy number alterations, and no genomic rearrangements. At the epigenetic level, global hypermethylation is the dominant process. Integrating transcriptional and methylation signatures identifies two BPH subgroups with distinct clinical features and signaling pathways, validated in two independent cohorts. Finally, mTOR inhibitors emerge as a potential subtype-specific therapeutic option, and men exposed to mTOR inhibitors show a significant decrease in prostate size. We conclude that BPH consists of distinct molecular subgroups, with potential for subtype-specific precision therapy.
Selo DaSilva